Osborne Clarke has advised the French-American investment fund Forepont Capital Partners (Forepont) in the Series A round of financing in Basecamp Vascular (BCV) led by Forepont alongside Palo Alto-based Neurotechnology Investors (NTI) and historical investors.
BCV has developed the first generation actuable mechatronic guide wire designed to provide practitioners with a direct access and navigation during minimally invasive endovascular procedures. The funding will accelerate the development of BCV’s range of active mechatronic guidewires, from manufacturing to go-to-market. BCV has already built a plant in Reims to secure in-house manufacturing and R&D evolution toward miniaturization.
Forepont is a healthcare and life science venture capital firm based in New York with a strong presence in Europe. Forepont invest in early-stage companies whose science and technology are intended to positively impact the lives of patients.
Osborne Clarke's teams were involved in the legal and HR due diligence, as well as in the drafting and negotiation of the legal documentation relating to the transaction.
Forepont advisors : Osborne Clarke
- Lead – M&A (Catherine Olive, partner, Florent Gurlie, counsel and Vincent d’Hauthuille, associate)
- Commercial/IP/IT (Xavier Pican, partner and Alice Vigne, associate)
- Employment (Jérôme Scapoli, partner, Antoine Boubazine, senior associate and Clara Di Pietro, associate)
- Real Estate (Stéphane Catays, partner and Franck-Olivier Klein, senior associate)
BCV / Founders advisors :
Reed Smith law firm (Marc Fredj, partner, Alex Ebangué and Antea Bonito, associates)